MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/prs.0000000000012186

Медицинская библиотека · Plastic and reconstructive surgery · 2025

Long-Term Outcomes of Oral Propranolol for Facial Infantile Hemangioma.

Zhou Jiangyuan, Zhang Zixin, Lan Yuru, Yang Min, Qiu Tong, Yang Kaiying, Zhang Xuepeng, Jiang Xian, Hou Fang, Shan Wei, Kong Feiteng, Hu Fan, Chen Siyuan, Ji Yi

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Oral propranolol is the first-line treatment for problematic infantile hemangiomas (IHs) requiring systematic therapy. Several retrospective studies have reported the successful treatment of facial IHs with propranolol. In this study, the authors conducted a prospective trial to evaluate the long-term outcomes of oral propranolol use in patients with facial IHs.

METHODS

The primary outcome was the clinical response 4 years after treatment.

RESULTS

A total of 272 patients were analyzed, including 38 patients (14.0%) with ulcerated IHs. Four years after treatment, propranolol treatment had resulted in no/minimal sequelae in 232 patients (85.3%). A total of 265 patients (97.4%) reported a durable response to propranolol therapy. Major rebound occurred in 16.9% of patients after propranolol discontinuation. Additional surgery and laser treatment were required in 8.1% and 8.8% of patients, respectively. Logistic regression analyses revealed that age 3 months or older (95% CI, 1.488 to 31.023; P = 0.013), nasal IH (95% CI, 2.143 to 97.571; P = 0.006), and hemangioma ulceration (95% CI, 2.673 to 49.034; P = 0.001) were independent factors predictive of long-term severe/significant sequelae. Segmental subtype (95% CI, 2.081 to 45.597; P = 0.004), mixed IH (95% CI, 3.249 to 26.841; P < 0.001), and lip IH (95% CI, 2.224 to 92.278; P = 0.005) were independent risk factors for major rebound.

CONCLUSIONS

In this large cohort of patients with facial IHs, propranolol treatment was effective and induced no/minimal sequelae at 4 years after treatment. However, long-term severe/significant sequelae and major rebound after propranolol treatment remain challenges.

Для цитирования: Zhou Jiangyuan, Zhang Zixin, Lan Yuru, Yang Min, Qiu Tong, Yang Kaiying, Zhang Xuepeng, Jiang Xian, Hou Fang, Shan Wei, Kong Feiteng, Hu Fan, Chen Siyuan, Ji Yi. Long-Term Outcomes of Oral Propranolol for Facial Infantile Hemangioma.. Plastic and reconstructive surgery. 2025. DOI: 10.1097/prs.0000000000012186.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.